Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca. As of 4/6/18, Rubraca® (rucaparib) is also approved by the FDA for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. FDA granted regular approval for Rubraca in this second, broader and earlier-line indication on a priority review timeline based on positive data from the phase 3 ARIEL3 clinical trial. Biomarker testing is not required for patients to be prescribed Rubraca in this maintenance treatment indication.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:CLVS
CUSIP18946410
Phone303-625-5000
Debt
Debt-to-Equity Ratio0.92
Current Ratio6.55
Quick Ratio5.74
Price-To-Earnings
Trailing P/E Ratio-9.50
Forward P/E Ratio-9.18
P/E GrowthN/A
Sales & Book Value
Annual Sales$55.51 million
Price / Sales46.06
Cash FlowN/A
Price / CashN/A
Book Value$7.50 per share
Price / Book6.49
Profitability
EPS (Most Recent Fiscal Year)($5.12)
Net Income$-346,390,000.00
Net Margins-545.80%
Return on Equity-79.02%
Return on Assets-33.90%
Miscellaneous
Employees360
Outstanding Shares52,550,000
Clovis Oncology (NASDAQ:CLVS) Frequently Asked Questions
What is Clovis Oncology's stock symbol?
Clovis Oncology trades on the NASDAQ under the ticker symbol "CLVS."
How were Clovis Oncology's earnings last quarter?
Clovis Oncology (NASDAQ:CLVS) issued its quarterly earnings data on Tuesday, May, 8th. The biopharmaceutical company reported ($1.54) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($1.36) by $0.18. The biopharmaceutical company had revenue of $18.50 million for the quarter, compared to the consensus estimate of $18.34 million. Clovis Oncology had a negative net margin of 545.80% and a negative return on equity of 79.02%. The firm's revenue was up 164.3% compared to the same quarter last year. During the same period in the previous year, the business posted ($1.33) earnings per share. View Clovis Oncology's Earnings History.
When is Clovis Oncology's next earnings date?
What price target have analysts set for CLVS?
13 analysts have issued 12-month price objectives for Clovis Oncology's stock. Their predictions range from $55.52 to $125.00. On average, they expect Clovis Oncology's share price to reach $87.2520 in the next twelve months. View Analyst Ratings for Clovis Oncology.
What are Wall Street analysts saying about Clovis Oncology stock?
Here are some recent quotes from research analysts about Clovis Oncology stock:
- 1. Cann analysts commented, "We believe the current status of the PARP inhibitor market is resulting in less predictable physician adoption than is typical in oncology settings. As a result, we are adjusting our Rubraca sales outlook for 2018-2022. Our outlook for Clovis Oncology is being adjusted to account for changes to our revenue estimates for 2018-2022, as a result of changes to our outlook for Rubraca. We are decreasing our Q2 2018 estimated Rubraca sales to $23.2 million from $44.8 million, and our 2018 estimated Rubraca sales by 27.2% to $126.0 million from our prior estimate of $173.0 million. We are reducing 2019 estimated Rubraca sales by 24.6% to $292.1 million from $387.6 million. We are making modest adjustments to 2020-2022E." (6/11/2018)
- 2. According to Zacks Investment Research, "Clovis’ Rubraca has not performed well in 2017 as it registered slower-than-expected sales. Nonetheless, Rubraca has bright prospects, given the tremendous demand for PARP inhibitors. Clovis is focused on continued approval for the drug. Rubraca is under review in EU for the same indication. A potential approval in Europe and in second-line setting in the United States will give a boost for the company. Several studies evaluating Rubraca in different types of ovarian cancer patients are ongoing. Clovis is looking for label expansion in second line or later maintenance treatment for advanced ovarian cancer. However, with just one approved product in the portfolio, Clovis is heavily dependent on Rubraca for growth, which concerns us. Clovis’ shares have underperformed the industry in the past six months. Loss estimates have narrowed ahead of Q1 results. Clovis has a mixed record of earnings surprises in the recent quarters." (5/1/2018)
- 3. JPMorgan Chase & Co. analysts commented, "2018 Procedure Growth Guidance Should Help Shares ISRG reported preliminary 4Q17 revenue of $892M (18% y/y), above our forecast of $865M and consensus’ estimates of $847M. Procedure growth of 17% came in higher than our 16.2% estimate and the Street’s 15.1% forecast. The sales breakout for 4Q included $457 in instrument revenue, $283 in system sales, and $153 for service, higher than our and Street estimates in each segment. 2018 guidance calls for 11-15% procedure growth, above our 10.9% forecast and in-line with consensus growth of 12.8%. This beat on revenue and procedure growth matched our expectations going into the report. Stellar revenue, strong procedure growth, and in-line 2018 guidance should boost shares today. There were 216 systems shipped in the quarter, well above our 180 unit estimate and the Street’s 187. Of these, 40 were shipped under operating lease agreements. However, implied system ASPs were $1.31M, below our modeled $1.55M and a more than $200Ksequential decline from Q3." (1/11/2018)
Who are some of Clovis Oncology's key competitors?
Some companies that are related to Clovis Oncology include Sarepta Therapeutics (SRPT), Nektar Therapeutics (NKTR), Genmab A/S (GNMSF), BeiGene (BGNE), Valeant Pharmaceuticals Intl (VRX), SAGE Therapeutics (SAGE), Alkermes (ALKS), Dr.Reddy's Laboratories (RDY), Agios Pharmaceuticals (AGIO), Catalent (CTLT), Loxo Oncology (LOXO), FibroGen (FGEN), Ionis Pharmaceuticals (IONS), United Therapeutics (UTHR) and GALAPAGOS NV/S (GLPG).
Who are Clovis Oncology's key executives?
Clovis Oncology's management team includes the folowing people:
- Mr. Patrick J. Mahaffy MA, Co-Founder, Chief Exec. Officer, Pres and Exec. Director (Age 55)
- Dr. Gillian C. Ivers-Read BSc, Co-Founder, Chief Regulatory Officer and Exec. VP of Technical Operations (Age 64)
- Mr. Daniel W. Muehl CPA, Sr. VP of Fin. and Principal Financial & Accounting Officer (Age 54)
- Dr. Lindsey Rolfe BSc, MB ChB, MRCP, FFPM, Chief Medical Officer and Exec. VP of Clinical, Preclinical Devel. & Pharmacovigilance (Age 50)
- Mr. Corwin Dale Hooks, Chief Commercial Officer and Sr. VP (Age 51)
Has Clovis Oncology been receiving favorable news coverage?
Media coverage about CLVS stock has been trending somewhat positive recently, Accern Sentiment reports. Accern identifies negative and positive news coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Clovis Oncology earned a news sentiment score of 0.24 on Accern's scale. They also assigned news headlines about the biopharmaceutical company an impact score of 47.57 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.
Who are Clovis Oncology's major shareholders?
Clovis Oncology's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Palo Alto Investors LP (7.53%), PointState Capital LP (4.84%), Franklin Resources Inc. (4.91%), Carmignac Gestion (2.87%), venBio Select Advisor LLC (2.22%) and Point72 Asset Management L.P. (2.20%). Company insiders that own Clovis Oncology stock include Gillian C Ivers-Read, James C Blair and Thorlef Spickschen. View Institutional Ownership Trends for Clovis Oncology.
Which institutional investors are selling Clovis Oncology stock?
CLVS stock was sold by a variety of institutional investors in the last quarter, including venBio Select Advisor LLC, PointState Capital LP, Franklin Resources Inc., Element Capital Management LLC, PNC Financial Services Group Inc., Wells Fargo & Company MN, C WorldWide Group Holding A S and Sector Gamma AS. Company insiders that have sold Clovis Oncology company stock in the last year include Gillian C Ivers-Read, James C Blair and Thorlef Spickschen. View Insider Buying and Selling for Clovis Oncology.
Which institutional investors are buying Clovis Oncology stock?
CLVS stock was acquired by a variety of institutional investors in the last quarter, including Palo Alto Investors LP, Summit Trail Advisors LLC, State of New Jersey Common Pension Fund D, Carmignac Gestion, Amundi Pioneer Asset Management Inc., Royal Bank of Canada, Trexquant Investment LP and Westfield Capital Management Co. LP. View Insider Buying and Selling for Clovis Oncology.
How do I buy shares of Clovis Oncology?
Shares of CLVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Clovis Oncology's stock price today?
One share of CLVS stock can currently be purchased for approximately $48.65.
How big of a company is Clovis Oncology?
Clovis Oncology has a market capitalization of $2.49 billion and generates $55.51 million in revenue each year. The biopharmaceutical company earns $-346,390,000.00 in net income (profit) each year or ($5.12) on an earnings per share basis. Clovis Oncology employs 360 workers across the globe.
How can I contact Clovis Oncology?
Clovis Oncology's mailing address is 5500 FLATIRON PARKWAY SUITE 100, BOULDER CO, 80301. The biopharmaceutical company can be reached via phone at 303-625-5000 or via email at [email protected]
MarketBeat Community Rating for Clovis Oncology (CLVS)
MarketBeat's community ratings are surveys of what our community members think about Clovis Oncology and other stocks. Vote "Outperform" if you believe CLVS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CLVS will underperform the S&P 500 over the long term. You may vote once every thirty days.
